Overview

Psilocybin Combined With Multidisciplinary Palliative Care in Demoralized Cancer Survivors With Chronic Pain

Status:
Not yet recruiting

Trial end date:
2022-08-31

Target enrollment:

Participant gender:

Summary

This phase I trial evaluates the side effects of psilocybin and how well it works under supportive care conditions in cancer survivors living with demoralization and chronic pain. Cancer patients often experience demoralization, which is characterized by feelings of hopelessness, loss of meaning, and existential distress. Psilocybin psychotherapy, together with multidisciplinary palliative and supportive care, may help treat the anxiety, depression, and chronic pain felt by cancer survivors - defined here as cancer patients from time of diagnosis through the end-of-life.

Phase:

Phase 1

Details

Lead Sponsor:

Emory University

Collaborator:

National Cancer Institute (NCI)

Treatments:

Psilocybin